Reimbursed Care Access in Chad

Currently classified as a strictly controlled substance under international psychotropic substance controls and, in practice, under national drug control regimes in most UN Member States including Chad; there is no publicly available evidence of authorised medical or reimbursed psilocybin therapy in Chad, and clinical use would be limited to authorised research protocols only. # #

Currently classified as a strictly controlled substance under international drug control (1971 Convention) and therefore subject to national prohibition in most countries; there is no publicly available evidence of authorised medical MDMA programs, reimbursement or routine clinical availability in Chad — access is effectively limited to approved clinical research where permitted. #

Esketamine (marketed as SPRAVATO® in jurisdictions where it is approved) is a licensed, regulated pharmaceutical for treatment‑resistant depression in certain high‑income regulatory jurisdictions but there is no public evidence that esketamine products or national reimbursement programs for esketamine exist in Chad; routine outpatient psychiatric/esketamine clinics and REMS‑style supervised programs that are required by manufacturers in markets such as the United States are not documented as operating in Chad. SPRAVATO® approvals are held by regulatory agencies such as the U.S. FDA (example: SPRAVATO approvals and label history). # #

Because esketamine products require specialized distribution/administration, monitoring and manufacturer‑mandated risk‑management programs in approved countries, their absence from public regulatory or health‑system documentation for Chad indicates that esketamine is not a reimbursed, widely available medical treatment there. Where esketamine is unavailable locally, the only lawful routes would be (1) importation under a specific regulatory/compassionate‑use pathway (if the national regulator permits) or (2) participation in an international multicentre clinical trial — neither of which is documented publicly for Chad.

Ketamine is an established, essential anaesthetic and analgesic used globally and is listed on the WHO Model List of Essential Medicines for injectable anaesthesia; in low‑ and middle‑income healthcare systems ketamine is routinely used in operating theatres and emergency care because of its safety profile for anaesthesia. # #

Regulatory context and reimbursement nuance in Chad: Chad’s public healthcare financing is limited and there is no publicly available national policy, guideline or reimbursement schedule that documents payment for ketamine when used specifically for psychiatric (off‑label) indications such as treatment‑resistant depression. Ketamine as an injectable anaesthetic is generally available within hospital settings where anaesthetic services are provided and is supplied and used under standard clinical pharmacy and hospital procurement practices; this use is for perioperative anaesthesia and emergency analgesia rather than for routine, reimbursed psychiatric infusion therapy. The international policy balance (WHO/UN) has historically emphasised maintaining access to ketamine for medical and surgical needs while limiting diversion — this underpins the continued medical availability of ketamine even when other psychedelics are strictly controlled. # #

Practical implications for patients in Chad: If a clinician sought to provide ketamine for psychiatric indications, it would be considered off‑label use, requiring local institutional oversight and private financing (out‑of‑pocket) in the absence of documented public reimbursement schemes; authorised, licensed esketamine nasal spray programs (with specific monitoring and distribution requirements) are not documented as operating or reimbursed in Chad. Relevant international guidance emphasises clinical monitoring and controlled administration when ketamine is used for psychiatric indications. #

Currently classified as a psychotropic substance under international control and, absent a nationally published exception, is treated as strictly controlled in most national drug regimes; there is no public evidence of licensed medical use or reimbursement for DMT in Chad — access is limited to authorised clinical research (if any). # #

Currently classified in the scope of internationally controlled hallucinogenic tryptamines and treated as a controlled substance in many jurisdictions; there is no evidence of authorised medical programs or reimbursement for 5‑MeO‑DMT in Chad — its lawful use would be confined to approved clinical research where explicitly authorised. #

Currently classified as a controlled/controlled‑status psychoactive substance in most countries with no authorised medical use outside approved clinical research; there is no public evidence of legal ibogaine treatment programs or reimbursement in Chad. # #

Although plant‑derived concoctions are treated variably worldwide, the principal psychoactive (DMT) is internationally controlled and most national regimes treat ayahuasca and DMT‑containing preparations as prohibited outside narrow religious or research exemptions; there is no public record of legal therapeutic or reimbursed ayahuasca programs in Chad, so use outside approved research would be unlawful. # #

Mescaline is a controlled hallucinogen under international schedules and is treated as a prohibited substance in most national legal systems; there is no documented medical licensing or reimbursement for mescaline in Chad and access is limited to authorised clinical research only. #

The 2C‑series phenethylamines (2C‑X) are synthetic hallucinogens that are routinely captured by national controlled‑substance laws and generic analogue provisions; there is no authorised medical or reimbursed therapeutic use reported for Chad — possession or supply outside approved research is subject to criminal penalties. #